3D hepatic organoid production from human pluripotent stem cells
Differentiation · 2024
DOI: 10.1016/j.diff.2023.100742 ↗At a glance
Journal article in Differentiation, 2024. Written by Zhe-Long Jin and 15 co-authors. Institution: Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, C…. Major MEDLINE topics: Induced Pluripotent Stem Cells, Pluripotent Stem Cells, Chemical and Drug Induced Liver Injury. Cited 3 times so far (Crossref); 51 references.
Abstract (original language)
Hepatic organoids might provide a golden opportunity for realizing precision medicine in various hepatic diseases. Previously described hepatic organoid protocols from pluripotent stem cells rely on complicated multiple differentiation steps consisting of both 2D and 3D differentiation procedures. Therefore, the spontaneous formation of hepatic organoids from 2D monolayer culture is associated with a low-throughput production, which might hinder the standardization of hepatic organoid production and hamper the translation of this technology to the clinical or industrial setting. Here we describe the stepwise and fully 3D production of hepatic organoids from human pluripotent stem cells. We optimized every differentiation step by screening for optimal concentrations and timing of differentiation signals in each differentiation step. Hepatic organoids are stably expandable without losing their hepatic functionality. Moreover, upon treatment of drugs with known hepatotoxicity, we found hepatic organoids are more sensitive to drug-induced hepatotoxicity compared with 2D hepatocytes differentiated from PSCs, making them highly suitable for in vitro toxicity screening of drug candidates. The standardized fully 3D protocol described in the current study for producing functional hepatic organoids might serve as a novel platform for the industrial and clinical translation of hepatic organoid technology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China; International Healthcare Innovation Institute (Jiangmen), Jiangh…
- Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, 28864, Republic of Korea.
- Department of Genetics, Yale Stem Cell Center, Yale Child Study Center, Yale School of Medicine, New Haven, CT, 06520, USA.
- Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China.
- Department of Surgery, College of Medicine, Chungbuk National University, Cheongju, 28864, Republic of Korea; Department of Surgery, Chungbuk National University Hospital, Cheongju, 28864, Republic of Korea.
- Department of Life Sciences, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea.
Cite
APA
Jin, Z. L., Xu, K., Kim, J., Guo, H., Yao, X., Xu, Y. N., Li, Y. H., Ryu, D., Kim, K. P., Hong, K., Kim, Y. J., Wang, L., Cao, Q., Kim, K. H., Kim, N. H., & Han, D. W. (2024). 3D hepatic organoid production from human pluripotent stem cells. Differentiation. https://doi.org/10.1016/j.diff.2023.100742
Vancouver
Jin ZL, Xu K, Kim J, Guo H, Yao X, Xu YN, et al. 3D hepatic organoid production from human pluripotent stem cells. Differentiation. 2024. doi:10.1016/j.diff.2023.100742
BibTeX
@article{Jin2024,
author = {Jin, Zhe-Long and Xu, KangHe and Kim, Jonghun and Guo, Hao and Yao, Xuerui and Xu, Yong-Nan and Li, Ying-Hua and Ryu, DongHee and Kim, Kee-Pyo and Hong, Kwonho and Kim, Yong-June and Wang, Lin and Cao, Qilong and Kim, Kyun-Hwan and Kim, Nam-Hyung and Han, Dong Wook},
title = {3D hepatic organoid production from human pluripotent stem cells},
journal = {Differentiation},
year = {2024},
doi = {10.1016/j.diff.2023.100742}
}
EUVIMED